Sanford C. Bernstein Analysts Give Merck KGaA (MRK) a €115.00 Price Target
Merck KGaA (FRA:MRK) received a €115.00 ($136.90) price objective from equities research analysts at Sanford C. Bernstein in a research report issued to clients and investors on Wednesday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s target price would indicate a potential upside of 25.22% from the company’s previous close.
MRK has been the subject of a number of other reports. Oddo Bhf set a €125.00 ($148.81) price target on Merck KGaA and gave the stock a “buy” rating in a report on Friday, November 10th. JPMorgan Chase & Co. set a €100.00 ($119.05) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Friday, October 6th. Citigroup set a €123.00 ($146.43) price target on Merck KGaA and gave the stock a “buy” rating in a report on Monday, September 25th. Goldman Sachs Group set a €105.00 ($125.00) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, September 19th. Finally, UBS Group set a €120.00 ($142.86) price target on Merck KGaA and gave the stock a “buy” rating in a report on Monday, January 8th. Twelve research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Merck KGaA has a consensus rating of “Hold” and an average price target of €107.57 ($128.06).
Shares of Merck KGaA (MRK) opened at €91.84 ($109.33) on Wednesday. The stock has a market capitalization of $11,990.00 and a PE ratio of 21.51. Merck KGaA has a fifty-two week low of €87.33 ($103.96) and a fifty-two week high of €115.00 ($136.90).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.